Efficacy of surufatinib in advanced Grade 3 neuroendocrine tumors: a real-world, national, multicenter study
Therapeutic Advances in Medical Oncology · 2026-07 · 18
DOI: 10.1177/17588359261464488 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 31.07.2026. Verfasst von Jian Wang und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, China. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the China Health & Medical Development Foundation.
Abstract (Originalsprache)
Background
Well-differentiated Grade 3 neuroendocrine tumors (G3 NETs) represent a heterogeneous entity with limited therapeutic standards. Surufatinib, a small-molecule inhibitor, has shown efficacy in G1/G2 NETs, but its specific role in the G3 subpopulation and optimal patient selection strategies remain to be elucidated.
Objectives
This study aimed to evaluate the real-world efficacy of surufatinib in G3 NETs and identify the factors that influenced progression-free survival (PFS).
Design
A national, multicenter, retrospective observational study.
Methods
We analyzed data from 77 patients with unresectable or metastatic G3 NETs (Ki-67 > 20%) treated with surufatinib across 15 centers in China between January 2021 and April 2024. The reporting of this study conforms to the STROBE statement. The primary endpoint was PFS. A multivariable Cox proportional hazards model was used to explore prognostic factors.
Results
The median Ki-67 index was 30% (range: 22%−70%), and 49 patients were of pancreatic origin. A total of 11 patients were treatment-naïve, and 27 patients received surufatinib-based combination therapy. The overall median PFS was 9.4 months (95% confidence interval: 8.5–13.0), and the objective response rate (ORR) was 22.1%. Patients with a Ki-67 index ⩽ 30% had longer PFS than the Ki-67 > 30% group (12.6 vs 9.0 months, hazard ratio = 0.270, p = 0.003). Combined treatment showed a numerical trend toward improved ORR (33.3% vs 16.0%, p = 0.08), but did not significantly prolong PFS compared to surufatinib monotherapy (9.7 vs 9.4 months, p = 0.64).
Conclusion
Surufatinib was a promising therapeutic option for G3 NETs. Prospective, larger-scale cohorts are warranted to confirm the efficacy and address the predictive markers for better patient selection.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Qilu Hospital of Shandong University, Jinan, China.
- The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
- Fudan University Shanghai Cancer Center, Shanghai, China.
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.
- Shanxi Cancer Hospital, Taiyuan, China.
ORCID-Profile: Jian Wang
Förderung
- the China Health & Medical Development Foundation
Zitieren
APA
Wang, J., Zhang, N., Liang, Y., Long, J., Chi, Y., Zhang, S., Bai, C., Wang, Y., Wu, Y., Hu, H., Hu, W., Huang, L., Liu, Y., Lv, H., Song, S., Suo, A., Wang, X., Zhang, L., Zhu, L., …, & Hao, J. (2026). Efficacy of surufatinib in advanced Grade 3 neuroendocrine tumors: a real-world, national, multicenter study. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261464488
Vancouver
Wang J, Zhang N, Liang Y, Long J, Chi Y, Zhang S, et al. Efficacy of surufatinib in advanced Grade 3 neuroendocrine tumors: a real-world, national, multicenter study. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261464488
BibTeX
@article{Wang2026,
author = {Wang, Jian and Zhang, Ning and Liang, Yun and Long, Jiang and Chi, Yihebali and Zhang, Suzhen and Bai, Chunmei and Wang, Yu and Wu, Yinying and Hu, Hanguang and Hu, Weiyu and Huang, Li and Liu, Ying and Lv, Huifang and Song, Shanai and Suo, Aili and Wang, Xiangling and Zhang, Lin and Zhu, Liming and Chen, Jie and Hao, Jing},
title = {Efficacy of surufatinib in advanced Grade 3 neuroendocrine tumors: a real-world, national, multicenter study},
journal = {Therapeutic Advances in Medical Oncology},
year = {2026},
volume = {18},
doi = {10.1177/17588359261464488}
}
EUVIMED